Spacetoon welcomes Ahmed Al-Ghandour for new animated series
Ahmed El-Ghandour is widely recognised for making complex scientific and historical concepts accessible through engaging and humorous storytelling.
Spacetoon has announced the addition of Ahmed Al-Ghandour, famously known as Al-Daee7, to its lineup. Al-Ghandour will lend his voice and signature charisma to the upcoming animated series, The Last Al-Daee7 on Earth, marking a collaboration that blends education, entertainment and humour.
As part of its 25th-anniversary celebrations, Spacetoon is unveiling this new animation, reaffirming its legacy of storytelling magic while stepping into a bold new chapter. The Last Al-Daee7 on Earth (آخر دحيح على الأرض) is set to premiere soon.
While plot details remain undisclosed, Spacetoon has teased an upcoming full reveal, urging fans to stay tuned with its iconic tagline: 'لا تنسى أن تبقى مع سبيستون' (Don't forget to stay with Spacetoon).
The announcement has already sparked massive buzz across social media, with hashtags like #Spacetoon25 and #AlDaee7 trending.
This isn't El-Ghandour's first venture into new platforms. In 2020, he introduced Mathaf El-Da7ee7 (El Da7ee7's Museum) on MBC's Shahid, where he applied his signature storytelling approach to explore historical topics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
4 days ago
- Gulf Today
Renowned Egyptian actress Samiha Ayoub passes away at 93
The renowned Egyptian actress Samiha Ayoub passed away on Tuesday, June 3, 2025, at the age of 93. Ayoub was one of the giants of Arab theatre, with a distinguished artistic career spanning from 1947 until her passing, encompassing theatre, cinema, and television. No official statement has been issued regarding the cause of her death. However, in early May, rumors circulated suggesting she was battling breast cancer. In a phone interview, Ayoub denied these rumors, stating: 'All these are false reports. I am in good health, and instead of spreading nice rumors, people spread bad ones.' She affirmed that her health was stable and denied any reports of suffering from tumors. Despite several media outlets reporting that she had breast cancer, Ayoub never officially confirmed the diagnosis. In previous remarks, she stated that she was in good health and continued to follow up with her doctor for treatment. She also expressed her eagerness to return to her audience with new and diverse roles. Speculation about her health intensified after she was recently seen with swelling in her hands, reportedly a result of lymphedema—a condition common among breast cancer patients. Lymphedema typically occurs following the removal of lymph nodes, leading to fluid retention and swelling in the affected limb. Ayoub was born on March 8, 1932, in the Shubra district of Cairo. She graduated from the Higher Institute of Dramatic Arts, where she was mentored by the renowned theatre director Zaki Tulaimat. He introduced her to the stage while she was still a student, casting her in the play Khedmet El-Malika (The Queen's Service), which marked the beginning of her artistic journey. Throughout her illustrious career, Ayoub starred in numerous plays, including Siket El-Salama, El-Sebnsa, El-Nadam, Phedra, El-Wazeer El-Aasheq, and El-Soltan El-Haer. She served as the director of the Modern Theatre in 1972 and later managed the National Theatre from 1975, holding the position for 14 years. Her theatrical repertoire included 170 plays, five of which she directed, including Maqalib Atia. Ayoub's legacy remains a cornerstone of Arab theatre and cinema, leaving behind an indelible mark on the artistic world.
Al Etihad
5 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
Broadcast Pro
31-05-2025
- Broadcast Pro
Palestinian film ‘A House in Jerusalem' now available on Shahid
The film is helmed by Muayad Alayan and co-written with Rami Alayan. Arabic streaming platform Shahid has released Palestinian filmmaker Muayad Alayan's third feature film, A House in Jerusalem. Directed by Muayad Alayan, who co-wrote the screenplay with Rami Alayan, A House in Jerusalem made its world premiere at the 2023 International Film Festival Rotterdam (IFFR). The film has garnered recognition at various renowned festivals worldwide, including the Boston Palestine Film Festival and the Seattle International Film Festival in the United States, as well as the Mostra de Valencia—Cinema del Mediterrani in Spain, the Athens Palestine Film Festival in Greece, and the Palestinian Film Festival in Australia. Notably, A House in Jerusalem was the sole Arab project selected for the 36th edition of the IFFR Pro's Production Market. Featuring an ensemble cast including Johnny Harris, Makran Khoury, Souad Feres, Miley Locke, and Sheherazade Makhoul Farrell, A House in Jerusalem follows the journey of young Rebecca, who is compelled to relocate with her father from the UK to Jerusalem in the hopes of finding solace and healing following her mother's sudden passing. As Rebecca settles into an old house in a neighbourhood known as the 'Valley of the Ghosts,' a series of mysterious events unfold, with Rebecca bearing the blame. The film delves deep into the mysteries of the house and the mystical city of Jerusalem, as Rebecca embarks on an enigmatic quest to uncover the secrets that lurk in the shadows of the house. The film's production involved collaboration among several entities, including PalCine Productions in Palestine, Wellington Films in the UK, Red Balloon Films in Germany, Metafora Production in Qatar, and Key Film. MAD Solutions is managing the distribution of the film across the Arab world. The film also received several development funds from the Doha Film Institute, Netherlands Film Fund, MOIN Film Fund Hamburg Schleswig-Holstein, British Film Institute, and French Consulate General Jerusalem. Additionally, it received the Filmmore Postproduction Award and the AFAC's Cinema Grant.
